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Targeted immunology for prevention and cure of VL
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Leishmaniasis is a neglected tropical disease caused by a group of
protozoan parasites of the genus Leishmania. Clinical presenta-
tion of leishmaniasis can range from cutaneous, mucocutaneous,
or visceral forms depending on the parasite species. Visceral leish-
maniasis (VL) caused by L. donovani and L. infantum is the severest
and one of the deadliest parasitic diseases of the tropics second
only to malaria (1). Nearly, 20,000–40,000 annual deaths are esti-
mated due to this disease (2). Except for the Indian subcontinent
and West Africa, VL is frequent in dogs, which serve as the major
reservoir for zoonosis (3).
Transmitted by the bite of an infected sandfly, Leishmania
endure in the phagolysomal compartment of macrophages by eva-
sion and attenuation of the microbicidal functions of the host
(4, 5). Leishmania has evolved as a successful parasite chiefly
by its ability to modulate the immunological and cyto-chemical
responses of the host following infection. The key strategy for
successful pathogenesis is to subvert the nitric oxide burst in the
host macrophage. This opportunistic parasite thus establishes a
safe niche in the inactivated phagocyte and uncontrolled para-
sitization in liver, spleen, and bone marrow leads to symptomatic
VL characterized by fever, weight loss, hepatosplenomegaly, and
anemia (3).
Since the pathogenesis of the disease is based on subversion and
modulation of both innate and adaptive arms of immunity, the
disease is opportunistic to immuno-suppression (6). Hence, com-
mencement of an appropriate immune response is a challenge for
the control of VL infection. Indeed, therapeutic drugs like SSG and
miltefosine are immuno-modulators that trigger Th1 responses
essential for activation of oxidative burst in the macrophages (7,
8). However, major limitations of narrow therapeutic index and
increasing incidence of resistance with currently used drugs for
VL are encumbrances in effective disease management. Recent
approaches like combination therapy, targeted delivery, and use of
immune-adjunct are efforts to bring down the effective doses of
these toxicity-associated drugs. Most promising are the prospects
of various immune-targeted therapeutic approaches for treatment
of VL (9). Various leishmanial antigens, cytokines, and antibod-
ies that initiate protective Th1-biased cell-mediated immune
responses used singly or as an adjunct to conventional chemother-
apy are potent immuno-chemotherapeutic agents for the cure
of VL (10, 11). Additionally, medicinal plants and their prod-
ucts have opened new dimensions in search of safer and cheaper
anti-leishmanial immuno-modulators. These phytochemicals are
not only promising as immuno-chemotherapeutic agents against
VL but also have potential as immuno-adjuvants and adjuncts
to chemotherapy for a number of other immuno-regulatory
diseases (12).
Since both cure and resilience to Leishmania infection depend
on the immunological status of the host, the antigens that can
trigger healing responses can also induce prophylactic immunity.
Therefore, identification of immunogens that can induce Th1
responses is the critical aspect of vaccine search against VL (13).
Although a number of defined antigens have been reported
to impart protective immunity against experimental VL, recent
trend of reverse vaccinology is a promising aspect for identi-
fication of key immunogens for a successful vaccine (13, 14).
This requires rational inputs and algorithm for identification
of a promising antigen from the whole proteome data analy-
sis in silico (15). One of the key inputs is to identify the
epitopes for activation of both CD4+Th1 and CD8+ T cells.
Indeed, several studies have attempted to generate epitope-based
vaccines from potent antigens that selectively targets MHC I
and MHC II. These multi-epitope-based synthetic vaccines were
found to stimulate Th1 and CD8+ T cell responses and can
be potentially used for prophylaxis against VL (16, 17). Since
antigen presenting cells determine the activation of specific lym-
phocyte subsets, targeting dendritic cells that are known for
activation of Th1 and CD8+ T cells can serve as an impor-
tant vaccination strategy against VL. Indeed, various reports of
antigen-pulsed DCs as vaccine against experimental VL have been
promising (18).
The vector (sandfly) salivary proteins play a pivotal role in
parasite pathogenesis. Indeed, the infective dose of Leishmania
parasites during natural transmission is much lower as compared
to saliva free infectious inoculums (19). This has been primarily
attributed to the initial immune responses to salivary component
triggered following sandfly bite, which enhances the infectivity
of Leishmania in the host. Rationally, priming the host against
a number of sandfly salivary proteins have been shown to induce
altered host immunity to the parasite imparting protection against
Leishmania infection (20, 21). Therefore, salivary proteins alone
or in combination with parasite antigens can be promising vaccine
components against VL (22).
However, most defined protein based vaccines are limited by
their inability to generate profound long lasting immunity. This
is in part due to lack of antigen persistence and multiplicity of
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antigens required to generate long lasting memory without a
suitable adjuvant (23). In fact, lifelong immunity gained through
natural infection is the gold standard of protection for VL. There-
fore, apart from triggering appropriate immune responses, the
immune correlates of long lasting protective immunity have to
be determined. This can be achieved in part by the partial mimic
of natural infection, which ensures antigen/parasite persistence
and multi-antigenicity required for robust long lasting immunity.
Although DNA vaccines can ensure antigen persistence, it is lim-
ited by multiplicity of antigens required and the potential adverse
effects associated.
For this very reason, several genetically modified live parasites
have been found to be the most efficient vaccination strategy (23,
24). However, despite reported success as a vaccination strategy
against experimental VL, none of the genetically modified organ-
isms have been approved for clinical trials. The primary concern is
the safety issue associated with live parasites. Possibility of revert
pathogenesis makes the use of live parasites speculative for human
administration. However, understanding the biomarkers of safety
of the live vaccines in human cell can be highly valuable in the
development of a successful vaccine against VL (25).
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